10/549241

S/N Unknown

JC17 Rec'd PCT/PTO P2TSEP 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

FERRARA et al.

Examiner:

Unknown

Serial No .:

Unknown

Group Art Unit:

Unknown

Filed:

September 12, 2005

Docket No.:

11669.0162USWO

Title:

COMPOSITIONS WITH HEMATOPOIETIC AND IMMUNE ACTIVITY

**CERTIFICATE UNDER 37 CFR 1.10**:

"Express Mail" mailing label number: EV 495843645 US

Date of Deposit: September 12, 2005

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450.

By: \\
Name: D

### **INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))**

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

### Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. At least some of the references were recently cited in an International Search Report mailed September 14, 2004.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Enclosed for the Examiner's information is a copy of the International Search Report.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

10/549241

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.

P.O. Box 2903

Minneapolis, MN 55402-0903

(612)332.5300

Bv:

Eric E. DeMaster

Reg. No.: 55,107

EED/mkc

23552

Dated: September 12, 2005

PATENT TRADEMARK OFFICE

Date Mailed: September 12, 2005

# JC17 Rec'd PCT/PTO 12 SEP 2005

FORM 1449\*

#### INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number: 11669.0162USWO

Application Number:

Applicant: FERRARA et al.

Filing Date: September 12,

Group Art Unit: Unknown

_	T	1	U.S. PATENT DOCUMEN	TS	1			
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS		G DATE OPRIATE	
						8.		
						•		
		FOI	REIGN PATENT DOCUM	IENTS				
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
	02/00711 A2	1/2002	WIPO					
	03/020892 A2	3/2003	WIPO					
	OTHER	DOCUMENT	'S (Including Author, Title,	Date, Pertinent l	Pages, Etc.)			
	LeCouter angiogene	LeCouter et al. "Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis" NATURE MEDICINE, vol. 8, no. 9, Sept. 2002 pp. 913-917.						
		Wechselberger et al. "The mammalian homologues of frog Bv8 are mainly expressed in spermatocytes" FEBS LETTERS, vol. 462, no. 1-2, Nov. 26, 1999, pp. 177-181.						
	LeCouter vol. 412,	et al. "Identific no. 6850, Aug. 1	eation of an angiogenic mito 30, 2001, pp. 877-884.	gen selective for	r endocrine gland e	ndothelium"	NATURE	

23552	
PATENT TRADEMARK OFFICE	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.